Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Wang Qi; Cook Sarah F.; Van Wart Scott A.; Mager Donald E.; Faderl Stefan

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

【24h】

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

机译：CPX-351血液学恶性肿瘤患者骨髓抑制患者的人口药代动力学（PK）/药效学（PD）建模和护理标准7 + 3疗法

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共2页
作者
Wang Qi; Cook Sarah F.; Van Wart Scott A.; Mager Donald E.; Faderl Stefan;
展开▼
作者单位

Jazz Pharmaceut Inc Palo Alto CA USA;

Enhanced Pharmacodynam Buffalo NY USA;

Enhanced Pharmacodynam Buffalo NY USA;

Enhanced Pharmacodynam Buffalo NY USA;

Jazz Pharmaceut Inc Palo Alto CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy [J] . Wang Qi, Cook Sarah F., Van Wart Scott A., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：CPX-351血液学恶性肿瘤患者骨髓抑制患者的人口药代动力学（PK）/药效学（PD）建模和护理标准7 + 3疗法
2. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate [J] . Lillian S., De Bono J., Higano C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：AZD8186研究1：I期研究评估AZD8186在晚期去势抵抗性前列腺癌（CRPC），鳞状非小细胞肺癌患者中的安全性，耐受性，药代动力学（PK），药效学（PD）和初步抗肿瘤活性，三联阴性乳腺癌以及PTEN缺陷/突变或PIK3CB突变/扩增的恶性肿瘤，单药治疗并与vistusertib（AZD2014）或醋酸阿比特龙合用
3. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate [J] . Lillian S., De Bono J., Higano C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：AZD8186研究1：I期研究，评估AZD8186在先进的阉割前列腺癌（CRPC），鳞状非小细胞肺癌患者中AZD8186的安全性，耐受性，药代动力学（PK），药效学（PD）和初步抗肿瘤活性，三重阴性乳腺癌和PTEN缺乏/突变或PIK3CB突变/扩增的恶性肿瘤，作为单药治疗，与Vistusertib（AZD2014）或乙酸酯组合
4. FPGA Implementation of a Pharmacodynamic and Pharmacokinetics (PK/PD) Model for Application in General Anesthesia [C] . Maria Camila Cardona García, David Alejandro Vallejo Santacruz, Daniel Felipe Valencia Vargas, IEEE ANDESCON Conference . 2018

机译：用于全身麻醉的药效和药代动力学（PK / PD）模型的FPGA实现
5. Mechanism-based pharmacokinetic/pharmacodynamic PK/PD modeling of corticosteroids and antiretrovirals. [D] . Fang, Jing. 2012

机译：皮质类固醇和抗逆转录病毒药物的基于机理的药代动力学/药效动力学PK / PD建模。
6. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy [O] . Balaji Agoram, Anne C. Heatherington, Marc R. Gastonguay 2006

机译：非循环性恶性肿瘤多周期化疗患者darbepoetin alfa药代动力学模型的建立和评估
7. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy [O] . Agoram, Balaji, Heatherington, Anne C., Gastonguay, Marc R. 2006

机译：非循环性恶性肿瘤多周期化疗患者darbepoetin alfa药代动力学模型的建立和评估

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

著录项

引文网络

相似文献

相关主题

期刊订阅